3 Healthcare Stocks Retail Investors Are Watching As Hiring Slows

The latest hiring data shows private sector job creation barely moving, yet healthcare stands out as one of the few pockets of growth. For investors, that mix of slower overall employment and concentrated gains in healthcare and services can reshape where capital feels comfortable. This article looks at how that backdrop, including a 7% jump in pay for job switchers and renewed focus on Federal Reserve policy, lines up with three healthcare stocks exposed to this news. You will see which companies could be positioned on the right side of these trends and why their risk profile matters now.

Krystal Biotech (KRYS)

Overview: Krystal Biotech is a commercial-stage biotech company that develops and sells genetic medicines, led by its approved therapy VYJUVEK for the rare skin disease dystrophic epidermolysis bullosa. The company is also advancing a broad pipeline in eye disease, lung conditions, oncology and aesthetic skin treatments.

Operations: Krystal Biotech generated US$440.5m in revenue from the discovery, development, manufacturing and commercialization of genetic medicines, all from the United States.

Market Cap: US$9.6b

Krystal Biotech operates at the intersection of two areas that investors are watching closely. Healthcare is one of the few areas still adding jobs, and Krystal focuses on high unmet medical need with VYJUVEK and a pipeline spanning cystic fibrosis, ophthalmology and oncology. The business is already profitable, reports very high gross margins on VYJUVEK and has seen analysts adjust price targets as new data and approvals arrive, such as UK authorization for DEB. At the same time, heavy reliance on a single marketed therapy, quarter-to-quarter revenue swings and rising costs tied to expansion mean the story involves real risk, especially if future trials or reimbursement decisions disappoint.

Krystal Biotech’s early commercial success and high gross margins can look straightforward, yet the real story sits in the balance between its single therapy, expanding pipeline and future trial risk. Get the fuller picture with the 3 key rewards and 1 important warning sign

BeOne Medicines (ONC)

Overview: BeOne Medicines is a global oncology company that develops and sells cancer treatments, led by commercial therapies such as BTK inhibitor BRUKINSA, immunotherapy TEVIMBRA and SYLVANT, alongside a large pipeline of targeted small molecules, antibodies and antibody drug conjugates for blood cancers and solid tumors.

Market Cap: US$35.9b

BeOne Medicines sits at the heart of where capital is flowing in healthcare, with oncology products like BRUKINSA and TEVIMBRA addressing areas of persistent demand while the broader jobs data still shows healthcare hiring resilience. Recent Q2 2026 results beat revenue and EPS expectations, management raised full year revenue and operating income guidance and the company continues to invest heavily in US manufacturing capacity, which can matter when supply chains come under pressure. At the same time, a rich valuation, heavy reliance on BRUKINSA and the CLL franchise, board turnover and insider selling mean you need to stay clear eyed about execution and competitive risk. The real question is how that mix of pipeline depth, funding structure and pricing pressure lines up against what you are paying for BeOne Medicines today.

BeOne Medicines appears to be an oncology story in which guidance upgrades and manufacturing build-out may be masking a deeper question. Get the 4 key rewards and 1 important warning sign to see what could shift the balance next.

Zevra Therapeutics (ZVRA)

Overview: Zevra Therapeutics is a commercial-stage biopharma company focused on rare and central nervous system diseases, with marketed treatments such as AZSTARYS for ADHD, OLPRUVA for urea cycle disorders and MIPLYFFA for Niemann Pick type C, alongside late stage candidates targeting idiopathic hypersomnia, narcolepsy and vascular Ehlers Danlos syndrome.

Operations: Zevra Therapeutics generates US$122.3m in revenue from its pharmaceuticals business.

Market Cap: US$621.9m

Zevra Therapeutics brings together elements that investors do not often see in rare disease stocks: a newly profitable business with strong return on equity and a pipeline that reaches into ultra rare and sleep disorder markets that still show structural demand, even as broader hiring slows. The company sits at the intersection of rising healthcare employment and sustained need for complex therapies. At the same time, it depends on small patient pools and faces pricing and regulatory pressure, highlighted by the recent European setback for MIPLYFFA. With the stock trading below some fair value estimates and analysts debating how far earnings can go, the gap between Zevra’s potential and what is currently priced in is presented as a key focus for investors.

Zevra Therapeutics looks like a rare disease story where newly profitable operations and small patient pools could be pulling in different directions. Step into the full risk reward picture with the 4 key rewards and 2 important warning signs (1 is major!)

The three healthcare stocks in this article are only a starting point, while the full Healthcare Sector screener surfaces 18 more companies with equally compelling stories tied to healthcare employment and services. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you, so you can focus on the healthcare stocks that best match your highest conviction ideas.

Take Control of Your Investment Journey

If BeOne Medicines or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Momentum Flies

Fresh stock ideas can move from quiet to crowded quickly. Spot early breakout potential while these picks stay under the radar for now. The clock is ticking. Consider acting soon based on your own research and judgment.

• Identify companies with strong cash positions before wider attention focuses on them by scanning the curated list of solid balance sheet and fundamentals (48 results).
• Explore potential AI-related stocks at an earlier stage by reviewing the focused group of 67 profitable AI stocks that aren't just burning cash.
• Research possible infrastructure opportunities by checking the hand picked list of 36 power grid technology and infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com